文献速递心血管技术与安全PETCT

使用124I-Evuzamitide正电子发射断层显像/计算机断层显像早期检测转甲状腺素蛋白心脏淀粉样变性

Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-05-28

本研究对25例受试者行124I-evuzamitide PET/CT显像,包括7例野生型ATTR-CA(均为Columbia I期)和18例ATTR变异等位基因携带者伴心肌病和/或神经病。11例99mTc-焦磷酸盐心脏显像Perugini 0或1级受试者出现124I-evuzamitide心脏摄取,提示该PET/CT可在99mTc-焦磷酸盐显像未检出时发现ATTR淀粉样沉积。心肌淀粉样负荷与疾病分期及超声心动图和生活质量指标呈中度至强相关。

要点

  • 124I-evuzamitide PET/CT可在99mTc-焦磷酸盐显像阴性或低摄取(Perugini 0或1级)时检出心肌ATTR淀粉样沉积。
  • 全部5例活检证实的变异型ATTR受试者及2例野生型ATTR且99mTc-焦磷酸盐显像阴性但心外活检证实ATTR的受试者均见124I-evuzamitide心肌摄取。
  • 心肌淀粉样负荷与疾病分期及超声心动图和生活质量指标呈中度至强相关。

核心结论

  • 124I-evuzamitide PET/CT显像可在99mTc-焦磷酸盐显像未检出时识别变异型转甲状腺素蛋白等位基因携带者和野生型受试者的心肌淀粉样沉积。

研究设计与样本

  • 研究纳入25例受试者行124I-evuzamitide PET/CT显像,其中7例野生型ATTR-CA(均为Columbia I期)、18例ATTR变异等位基因携带者伴心肌病和/或神经病;心肌摄取以左心室注射剂量百分比和心脏淀粉样活性(平均特定摄取值×体积)计算,参考标准包括99mTc-焦磷酸盐心脏显像Perugini分级、活检和超声心动图。

关键影像表现/征象

  • 11例ATTR且99mTc-焦磷酸盐心脏显像Perugini 0或1级的受试者出现124I-evuzamitide心脏摄取。
  • 5例活检证实的变异型ATTR受试者全部显示124I-evuzamitide心肌摄取。
  • 2例野生型ATTR受试者99mTc-焦磷酸盐显像阴性(0级)但心外活检显示ATTR,亦显示124I-evuzamitide心肌摄取。

诊断标准与关键数值

  • 99mTc-焦磷酸盐显像Perugini 2或3级摄取对ATTR-CA高度特异,在无单克隆蛋白时敏感度约70%。
  • 124I-evuzamitide心肌摄取定义为左心室注射剂量百分比(平均活度浓度×体积/注射活度)及心脏淀粉样活性(平均特定摄取值×体积),取血池以上摄取的体素计算。

临床应用与阅片要点

  • 124I-evuzamitide PET/CT显像可能检测到99mTc-焦磷酸盐心脏闪烁显像未显示的ATTR淀粉样沉积。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Early detection of transthyretin cardiac amyloidosis (ATTR-CA) is vital, because currently available therapies are most effective early in the disease course. Although Perugini grade 2 or 3 uptake on scintigraphy using bone-avid tracers such as 99mTc-pyrophosphate is highly specific for ATTR-CA, absent monoclonal proteins, sensitivity is about 70%. Positron emission tomographic (PET)/computed tomographic (CT) imaging using the novel radiolabeled heparan sulfate proteoglycan-binding peptide 124I-evuzamitide has been shown to be useful for quantifying cardiac amyloid load in systemic amyloidosis.

OBJECTIVES: The aim of this study was to quantify myocardial 124I-evuzamitide PET uptake and compare diagnostic performance with that of 99mTc-pyrophosphate in patients with ATTR-CA and carriers.

METHODS: Twenty-five subjects underwent imaging using 124I-evuzamitide PET/CT imaging: 7 with wild-type ATTR-CA (all Columbia stage I) and 18 transthyretin amyloidosis (ATTR) variant-allele carriers with cardiomyopathy and/or neuropathy. Myocardial uptake was determined as left ventricular percentage of injected dose (mean activity concentration × volume/injected activity) and cardiac amyloid activity (mean specific uptake value × volume) within voxels with uptake above blood pool.

RESULTS: Eleven subjects with ATTR and Perugini grade 0 or 1 99mTc-pyrophosphate cardiac scans had cardiac uptake of 124I-evuzamitide, suggesting that 124I-evuzamitide PET/CT imaging may detect ATTR amyloid deposits when 99mTc-pyrophosphate cardiac scintigraphy does not. 124I-evuzamitide showed myocardial uptake in all 5 subjects with variant ATTR with biopsy-proven disease and in 2 subjects with wild-type ATTR and negative (grade 0) results on 99mTc-pyrophosphate scans but extracardiac biopsies showing ATTR. Myocardial amyloid load was moderately to strongly correlated with disease stage and with echocardiographic and quality-of-life measures.

CONCLUSIONS: 124I-evuzamitide PET/CT imaging can identify myocardial amyloid in variant transthyretin allele carriers and wild-type subjects when 99mTc-pyrophosphate does not. (Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR; NCT05635045).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Smiley DA, Einstein AJ, O'Gorman KJ, et al. Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography. JACC Cardiovasc Imaging. 2025. PMID: 40439628. doi:10.1016/j.jcmg.2025.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。